Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for TuHURA Biosciences, Inc. (HURA : NSDQ)

• Company Description    TuHURA Biosciences Inc. is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA Biosciences Inc., formerly known as Kintara Therapeutics Inc., is based in SAN DIEGO. Number of Employees: 22

• Price / Volume Information    Yesterday's Closing Price: $2.50 Daily Weekly Monthly 20 Day Moving Average: 653,359 shares Shares Outstanding: 63.68 (millions) Market Capitalization: $159.21 (millions) Beta: -0.01 52 Week High: $3.90 52 Week Low: $0.41 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 9.17% 3.84% 12 Week 54.32% 42.66% Year To Date 230.38% 184.31%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10500 UNIVERSITY CENTER DR. SUITE 110 - TAMPA,FL 33612 USA ph: 813-875-6600 fax: 604-608-5685 tuhurabio@jtcir.com https://tuhurabio.com

• General Corporate Information    Officers James A. Bianco - Chief Executive Officer; President and Director Dan Dearborn - Chief Financial Officer James Manuso - Director Alan List - Director George Ng - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 898920103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: - Share - Related Items Shares Outstanding: 63.68 Most Recent Split Date: 10.00 (0.03:1) Beta: -0.01 Market Capitalization: $159.21 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.45 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.95 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 13.33% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -156.12 12/31/25 - -182.40 09/30/25 - -196.68 ROA 03/31/26 - -105.38 12/31/25 - -117.49 09/30/25 - -123.41 Current Ratio 03/31/26 - 1.15 12/31/25 - 0.78 09/30/25 - 0.40 Quick Ratio 03/31/26 - - 12/31/25 - 0.78 09/30/25 - 0.40 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 0.36 12/31/25 - 0.34 09/30/25 - 0.32 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©